With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through our nearly 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|The role of vitamin D in hepatoblastoma formation and prevention||Brigham and Women's Hospital / Wolfram Goessling, MD/PhD||Innovation Grants||2012||Massachusetts|
|Searching for genetic vulnerabilities in osteosarcoma through genome-wide RNAi screening||Dana-Farber Cancer Institute / Stuart Orkin, MD||Innovation Grants||2012||Massachusetts|
|Developing Immune-modulatory Strategies Against Primary and Metastatic Tumors in the Central Nervous System||Case Western Reserve University / Alex Huang, MD, PhD||Innovation Grants||2012||Ohio|
|Novel STAT3 drug development for childhood osteosarcoma therapy using drug repositioning||Research Institute at Nationwide Children's Hospital / Jiayuh Lin, PhD||Innovation Grants||2012||Ohio|
|Mechanisms of LYL1-associated T-ALL development||Baylor College of Medicine / Margaret Goodell, PhD||Innovation Grants||2012||Texas|
|V alpha-invariant NKT cells as a novel platform for cancer immunotherapy||Baylor College of Medicine / Leonid Metelitsa, MD, PhD||Innovation Grants||2012||Texas|
|Casein Kinase 1 alpha Agonists as Novel Medulloblastoma Inhibitors||University of Miami Miller School of Medicine / David Robbins, PhD||Innovation Grants||2012||Florida|
|A novel mouse model of rhabdomyosarcoma||Vanderbilt University Medical Center / Chin Chiang, PhD||Innovation Grants||2012||Tennessee|
|Identification of predisposition genes for Ewing sarcoma segregating in high-risk pedigrees||Huntsman Cancer Institute / Lisa Cannon-Albright, PhD||Innovation Grants||2012||Utah|
|Identification and validation of new therapeutic targets in pediatric leukemia through an aneuploidy-based synthetic lethality screen||Dana-Farber Cancer Institute / David Pellman, MD||Innovation Grants||2012||Massachusetts|